Suicidality and relief of depressive symptoms with intermittent theta burst stimulation in a sham‐controlled randomized clinical trial
Open Access
- 14 October 2022
- journal article
- research article
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 146 (6), 540-556
- https://doi.org/10.1111/acps.13502
Abstract
Objectives Suicidality is a serious public health problem and is closely associated with the severity of depression. In this work, we examined the effects of accelerated intermittent theta burst stimulation (iTBS) on suicidal status, risk factors for suicide, and severity of depressive symptoms in subjects with major depressive disorder (MDD). Methods We present data from a quadruple-blind (patient, care provider, investigator, rater) sham-controlled crossover randomized clinical trial. During a 6-week observation period, each participant underwent 2 weeks of stimulation - each week with 20 sessions of active or sham iTBS. A suicide score was created using a composite of individual items from Montgomery-angstrom sberg Depression Scale (MADRS), Hamilton Depression Scale, and Beck Depression Inventory. The severity of depression was determined by MADRS total scores. In addition, we used demographic and Columbia Suicidality Rating Scale information to assess suicide risk. Results Among 81 participants, we observed a significant reduction in suicidality and this change was positively correlated with a change in depressive symptoms. A significant difference between active and sham iTBS provided evidence for antidepressant effects. Higher changes in levels of anxiety and impulsiviness also correlated with larger changes in suicidality. Conclusions As neither suicide nor other serious adverse events were evidenced, this intervention was a safe and viable procedure to reduce suicidality and severity of depressive symptoms. Moreover, we identified more pronounced anti-suicidal effects in those with higher risk profiles. Unlike MADRS, composite suicidal scores did not provide evidence of an effect between stimulation conditions in this crossover design study. Even so, based on our promising results, parallel and larger studies could contribute to a better characterization of the anti-suicidal placebo effect and the benefit of using iTBS against suicidal symptoms.Keywords
This publication has 79 references indexed in Scilit:
- A Systematic Review of Comparative Efficacy of Treatments and Controls for DepressionPLOS ONE, 2012
- Treatment-resistant depression: therapeutic trends, challenges, and future directionsPatient Preference and Adherence, 2012
- Relationship Between a History of a Suicide Attempt and Treatment Outcomes in Patients With DepressionJournal of Clinical Psychopharmacology, 2011
- Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdoseThe British Journal of Psychiatry, 2010
- Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant DepressionBiological Psychiatry, 2009
- Suicidal risk factors and completed suicide: meta-analyses based on psychological autopsy studiesEnvironmental Health and Preventive Medicine, 2008
- Measuring depression: comparison and integration of three scales in the GENDEP studyPsychological Medicine, 2007
- Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety reviewBMJ, 2005
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960